A MEDVi alternative that shows the pharmacy and the price before you pay
MEDVi does not show the price for your dose or say which pharmacy will fill your order before you buy, and its Terms say the final charge “may fluctuate” with the medication and the pharmacy. Its GLP-1 page advertises $99 for the first month and refills “locked in at $199.” At Temi, you see each partner pharmacy's name and its price for your dose, and the $39 prescription service, before you pay. If prescribed, compounded semaglutide costs from $59.99 per vial at the starting dose in California. A licensed physician decides, and your card is held at checkout, not charged.
MEDVi prices from its GLP-1 page and Terms, read November 5, 2026.
- Pharmacy and price shown before you pay
- Card held, not charged, at checkout
- 24/7 support by email or in-app message
TL;DR: Temi vs MEDVi quick verdict
- Price for your dose
- Each partner pharmacy's price, before you pay
- Pharmacy
- Named before you pay; you choose it
- Prescription service
- $39 per prescription, or included with Temi Care
- When you are charged
- When the physician decides
- Renews
- Only when you order again
You see the pharmacy's name and its price for your dose before you pay.
- Price for your dose
- Not shown before intake, per its GLP-1 page
- Pharmacy
- One of three listed partners, not named before you buy, per its Terms
- Final charge
- It “may fluctuate,” per its Terms
- Advertised price
- $99 first month, then $199 refills, per its GLP-1 page
- Billing
- A recurring 28-day cycle, per its replies on BBB
FDA sent MEDVi a warning letter on February 20, 2026, about claims on medvi.io.
About Temi
Temi is a prescription service, not a pharmacy. You answer a health questionnaire, choose a partner pharmacy and see its price for your dose, and a licensed physician decides whether to prescribe. If prescribed, the pharmacy ships the medication to you. Temi charges for the review, not the prescription.
- $39 prescription service per prescription, or $449 a year with Temi Care, which includes it on eligible orders
- Decided by Kevin Brandstetter, M.D. or another physician licensed in the state you are in
- You pick the partner pharmacy, by name and its price for your dose, before you pay
- usetemi.com holds LegitScript Healthcare Merchant Certification
- A person answers 24/7 by email or in-app message: [email protected]
About MEDVi
MEDVi, LLC sells weight-loss programs built on compounded GLP-1 medication. Its homepage says: “OpenLoop Health clinicians retain the decision to prescribe compounded GLP-1s to patients.” Its footer says medical treatment is provided by “CareGLP Affiliated P.C.s,” and OpenLoop Health.
- Lists three partner pharmacies in its Terms: Triad Rx in Daphne, Alabama; RedRock Pharmacy in St. George, Utah; and Beaker Pharmacy & Compounding in McKinney, Texas
- Does not say which pharmacy fills your order before you buy
- Names no individual prescriber on its site
- Its GLP-1 page fine print says the compounded medications “are not FDA-approved or evaluated for safety, efficacy, or quality.”
Feature comparison: Temi vs MEDVi
Price for your dose, before you pay
- Temi
- Yes, for each partner pharmacy
- MEDVi
- Not shown before intake, per its GLP-1 page
Pharmacy named before you pay
- Temi
- Yes, you choose it
- MEDVi
- One of three listed partners; not named for your order
You pick the pharmacy
- Temi
- Yes, among partner pharmacies, by name and price
- MEDVi
- No: “our system does not allow us to select a preferred pharmacy, but the agents who received your request made every effort to explore possible options on your behalf,” it said on BBB in 2025
When your card is charged
- Temi
- When the physician decides; held until then
- MEDVi
- At enrollment, per its replies on BBB
Renewal
- Temi
- Only when you place a new order
- MEDVi
- Recurring 28-day billing cycle, per its replies on BBB
Prescribing physician named
- Temi
- Kevin Brandstetter, M.D., or another physician licensed in your state
- MEDVi
- No individual prescriber named on its site
Compounded tirzepatide
- Temi
- From $106.99 per vial at the starting dose in California, if prescribed
- MEDVi
- Not listed on its GLP-1 page
MEDVi figures are from glp1.medvi.org, home.medvi.org, and MEDVi's replies to BBB complaints and a BBB review, read November 5, 2026. MEDVi is its name, not ours.
The FDA letter, the lawsuits, the price history, and the reviews, with sources: Is MEDVi legit?
What the public record shows about MEDVi
As of November 5, 2026. Each card links its source.
An FDA warning letter
FDA's warning letter to MEDVi, LLC, dated February 20, 2026, concerns claims on medvi.io. It says the pictured labels suggested “MEDVi is the compounder of those drugs when in fact it is not.” It also says: “Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.” FDA's index shows no close-out letter. In a statement Futurism reported, MEDVi said the letter “was directed at an affiliate marketing agency.” A warning letter states FDA's position; it is not a court ruling.
Two privacy class actions, six suits in all
Two class actions filed in April 2026 in the Central District of California, E.P. v. Medvi LLC and J.F. v. Medvi LLC, allege that MEDVi told users their information is “never shared” while sending intake-page addresses that contained users' email addresses to Google. These are allegations. MEDVi has moved to compel arbitration, with a hearing set for November 19, 2026. CourtListener's RECAP archive lists six federal suits naming MEDVi, LLC as a defendant since May 2025: these two, an anti-spam suit (8:26-cv-00641), and three text-message suits under the federal Telephone Consumer Protection Act (1:25-cv-22185, 2:25-cv-11282, 2:26-cv-04323). Three have been dismissed. Each is an allegation, not a finding.
A data breach at OpenLoop
OpenLoop Health, the clinician network MEDVi's site names, reported a breach affecting 716,000 people to HHS (submitted March 17, 2026), as the HHS breach portal lists it (search OpenLoop Health). SecurityAffairs reported the same figure for a January 2026 breach at OpenLoop. The named plaintiff in a February 19, 2026 class action against OpenLoop over the January 2026 breach alleges she used MEDVi in 2025 (S.D. Iowa 4:26-cv-00083). MEDVi is not a defendant in that suit.
“Featured and advertised in”
Its GLP-1 page shows “Proud To Be Featured And Advertised In” above the Bloomberg, Forbes, Healthline, WebMD, Fortune, Fast Company, and New York Times logos. In May 2025, Futurism found no MEDVi coverage in the New York Times or Bloomberg, apart from a Forbes Health roundup listing. The Times later reported that MEDVi had “merely advertised there,” as Techdirt quoted it.
What its guarantee says
On February 17, 2026, a feature strip on MEDVi's refund policy page read “MEDVi money back guarantee”; by March 5 the strip read “MEDVi guarantee” and the policy added “There is no guarantee of results or effectiveness due to your participation in the Subscription Services.” The current policy keeps a version of that sentence. As of November 5, 2026, a GLP-1 page on quad.medvi.org still says “we guarantee you'll lose weight or your money back.” Its medical consent says “There are no refunds or exchanges” and has patients certify they “will not dispute the payments with my credit card company.”
Its own replies on BBB
MEDVi's replies to BBB complaints say “recurring charges may process regardless of whether a refill intake has been completed” (June 17, 2026). Another says “refund requests during an active billing cycle must be submitted at least 72 hours prior to the billing date,” and that if a doctor advised stopping treatment, “we would need documentation or a note from your PCP in order to further review refund eligibility” (May 14, 2026).
Ads under doctor personas
In April 2026, Drug Discovery & Development counted more than 5,000 active Meta ads for MEDVi, many under apparently fabricated doctor personas. MEDVi's statement to Futurism said it had only recently become aware of those ads.
BBB
BBB rates MEDVi F, which BBB calls its opinion of how a business is likely to interact with its customers. It lists 789 complaints in three years, 657 of them in the last 12 months, and “Failure to respond to 147 complaint(s).” Customer reviews there average 1.82 of 5 across 639 reviews. BBB asks readers to consider a company's size and volume of transactions.
Trustpilot
An archived copy of MEDVi's Trustpilot page from March 13, 2026 shows a TrustScore of 4.5 across 10,676 reviews, with reviews labeled “Invited.” The current page could not be read.
Pricing comparison: Temi vs MEDVi
Temi
$59.99 per vial, compounded semaglutide
At the starting dose in California, if prescribed. Higher doses cost more.
$106.99 per vial, compounded tirzepatide
At the starting dose in California, if prescribed. Higher doses cost more.
$39 per prescription, prescription service
Included with Temi Care, $449 a year, on eligible orders.
Every partner pharmacy's price for your dose is on the compounded semaglutide and compounded tirzepatide pages before you pay. Your card is held at checkout and charged when the physician decides; if the physician declines, only the prescription service is charged.
MEDVi
No dose price before intake
Its GLP-1 page shows no price for a specific dose, and its Terms say the final charge “may fluctuate contingent upon the prescribed medication and the chosen pharmacy for order fulfillment.”
$99 first month, compounded semaglutide
“FALL Sale! Only $99,” per its GLP-1 page.
$199 per refill
Its GLP-1 page says refills are “locked in at $199.”
$249 GLP-1 tablets, starting price
Per its GLP-1 page.
$99 membership plus medication cost, Wegovy and Zepbound
The same page also says “No membership or hidden fees!”
Earlier archived copies of medvi.org advertised $179 for the first month and refills “locked in at $299.” Its replies on BBB describe a recurring 28-day billing cycle, which is 13 charges a year. Prices read November 5, 2026.
Final verdict: Temi vs MEDVi
Choose Temi if you want to see the pharmacy and the price for your dose before you pay, a named physician who decides, and an order that renews only when you place another.
Before you start
Compounded semaglutide and compounded tirzepatide are not FDA-approved generics of the brand-name products. A licensed 503A compounding pharmacy prepares each one for a single prescription.
A licensed physician decides whether to prescribe, and the prescription service pays for that review whatever the decision. Temi prescribes for patients physically located in Arizona, California, Colorado, Delaware, Florida, Michigan, Missouri, New York, North Carolina, Ohio, Pennsylvania, Texas, and Wisconsin. Temi does not treat patients under 18 and does not provide emergency care.
FAQ
Questions about Temi vs MEDVi
What is the difference between Temi and MEDVi?
Temi shows each partner pharmacy's price for your dose, and the $39 prescription service, before you pay. A licensed physician decides whether to prescribe, your card is held until then, and an order never renews by itself.
MEDVi sells a weight-loss program with an advertised price per cycle. Its site shows no price for your dose and names no pharmacy for your order before you buy. Its GLP-1 page advertised $99 for the first month and refills “locked in at $199” as of November 5, 2026, and its replies on BBB describe a recurring 28-day billing cycle.
How much does MEDVi cost?
Its GLP-1 page shows no price for a specific dose before intake, and its Terms say the final charge “may fluctuate” with the medication and the pharmacy. As read November 5, 2026, the page advertises “FALL Sale! Only $99” for the first month and says refills are “locked in at $199.” GLP-1 tablets start at $249, and Wegovy and Zepbound are a “$99 Membership + Medication Cost.” Earlier copies of medvi.org advertised $179 for the first month and $299 refills.
Did the FDA send MEDVi a warning letter?
Yes. FDA's drug center sent MEDVi, LLC a warning letter dated February 20, 2026, about claims on medvi.io, including “Same active ingredient as Wegovy® and Ozempic®.” FDA said such claims imply FDA approval or evaluation that compounded drugs do not have. Its warning-letter index showed no close-out letter as of November 5, 2026. A warning letter is FDA's position, not a court ruling.
Which pharmacy fills MEDVi orders?
Its Terms list three partner pharmacies: Triad Rx in Daphne, Alabama; RedRock Pharmacy in St. George, Utah; and Beaker Pharmacy & Compounding in McKinney, Texas. Its site does not say which one fills a given order before you buy. In an April 2025 reply on BBB to a customer who asked for a specific pharmacy, MEDVi wrote: “Unfortunately, our system does not allow us to select a preferred pharmacy, but the agents who received your request made every effort to explore possible options on your behalf.”
Who prescribes at MEDVi?
Its homepage says: “OpenLoop Health clinicians retain the decision to prescribe compounded GLP-1s to patients.” Its footer says medical treatment is provided by “CareGLP Affiliated P.C.s,” and OpenLoop Health. The site names no individual prescriber.
Is Temi a MEDVi alternative?
Yes, for compounded semaglutide or tirzepatide. You answer a health questionnaire, choose a partner pharmacy and see its price for your dose, and a licensed physician decides whether to prescribe. If prescribed, the pharmacy ships the medication to you. Temi serves patients located in Arizona, California, Colorado, Delaware, Florida, Michigan, Missouri, New York, North Carolina, Ohio, Pennsylvania, Texas, and Wisconsin.
How much does Temi cost?
Two parts, both shown before you pay. The medication is each partner pharmacy's price for your dose: if prescribed, from $59.99 per vial of compounded semaglutide and $106.99 per vial of compounded tirzepatide at the starting dose in California, and more at higher doses. The prescription service is $39 per prescription, or included with Temi Care, $449 a year, on eligible orders.
When does Temi charge my card?
At checkout your card is held, not charged. Temi charges when the physician decides your request, or shortly before the hold expires within 7 days. If the physician declines, Temi charges only the prescription service, which pays for the review either way.
Does a Temi order renew automatically?
No. Each order is one order. When you need more medication, you start a new request and a physician reviews it again. Temi Care, the optional membership, renews yearly.
Is compounded semaglutide the same as Wegovy or Ozempic?
No. Compounded semaglutide and compounded tirzepatide are not FDA-approved generics of the brand-name products. A licensed 503A compounding pharmacy prepares each one for a single prescription, and a licensed physician decides whether either is right for you.
What is the Temi Satisfaction Guarantee?
Tell the team you are not satisfied with Temi's clinical service and why, and the review fee is refunded. A decision you did not want is not by itself a refund, because the fee pays for the physician's review either way. Money Temi collected for something it did not deliver is always refunded.
Which states does Temi cover?
Temi prescribes for patients physically located in Arizona, California, Colorado, Delaware, Florida, Michigan, Missouri, New York, North Carolina, Ohio, Pennsylvania, Texas, and Wisconsin. What matters is the state you are in when you submit the request.
More from Temi
Is MEDVi legit?
The FDA letter, the lawsuits, the prices, and the reviews, with sources.
Compounded semaglutide
Each partner pharmacy's price per vial, by dose.
Compounded tirzepatide
Each partner pharmacy's price per vial, by dose.
GLP-1 cost calculator
Estimate a year of compounded or brand-name GLP-1 costs.